Healio Tyrosine Kinase Inhibitors and Their Role in Redefining Retinal Care
Patients with retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) face significant challenges with current anti-vascular endothelial growth factor (VEGF) therapies, including frequent intravitreal injections, which disrupt daily life and contribute to poor adherence and suboptimal outcomes. These burdens are compounded by systemic management needs, psychological distress, and financial costs. Emerging treatments like tyrosine kinase inhibitors (TKIs) offer promise by targeting complementary pathways in angiogenesis and providing sustained-release options to reduce injection frequency. Data from ongoing TKI studies show encouraging results in improving durability, adherence, and visual outcomes. While no TKIs are currently approved for retinal diseases, these therapies are advancing through clinical trials, potentially transforming treatment paradigms. In this CE activity, expert faculty summarize the challenges associated with anti-VEGF use, review the rationale for targeting tyrosine kinases in nAMD and DR, and summarize the most recent clinical trial data on TKIs.
Cost: Free
View Offer chevron_rightDetails
Patients with retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) face significant challenges with current anti-vascular endothelial growth factor (VEGF) therapies, including frequent intravitreal injections, which disrupt daily life and contribute to poor adherence and suboptimal outcomes. These burdens are compounded by systemic management needs, psychological distress, and financial costs. Emerging treatments like tyrosine kinase inhibitors (TKIs) offer promise by targeting complementary pathways in angiogenesis and providing sustained-release options to reduce injection frequency. Data from ongoing TKI studies show encouraging results in improving durability, adherence, and visual outcomes. While no TKIs are currently approved for retinal diseases, these therapies are advancing through clinical trials, potentially transforming treatment paradigms. In this CE activity, expert faculty summarize the challenges associated with anti-VEGF use, review the rationale for targeting tyrosine kinases in nAMD and DR, and summarize the most recent clinical trial data on TKIs.
Topics Covered
Tyrosine Kinase Inhibitors
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Recognize the challenges associated with anti-VEGF use for patients with nAMD or DR and how these challenges lead to undertreatment.
- Review the rationale for targeting tyrosine kinases in the management of patients with nAMD or DR.
- Summarize the most recent clinical data on TKIs for treating patients with nAMD.
Target Audience
The intended audience for this activity is retina specialists involved in the management of patients with nAMD or DR.
Additional credit info
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.